Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy ± biologic: Findings from 9,092 pts in the ARCAD database.

被引：8
|
作者：
Ou, Fang-Shu
Hubbard, Joleen Marie
Kasi, Pashtoon Murtaza
Dixon, Jesse
Van Cutsem, Eric
Saltz, Leonard
Schmoll, Hans-Joachim
Punt, Cornelis J. A.
Goldberg, Richard M.
Paulo
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.3535
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3535
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Efficacy and safety findings from a phase II study of capecitabine (X) as first-line therapy in Japanese patients (pts) with advanced/metastatic colorectal cancer (MCRC).
    Shirao, K
    Doi, T
    Hatake, K
    Arai, Y
    Yamaguchi, K
    Hyodo, I
    Tamura, T
    Takemiya, S
    Takiuchi, H
    Sakata, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 294S - 294S
  • [22] Clinical outcomes of patients (Pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) treated with first-line (1L) chemotherapy regimens
    Parikh, A.
    Tabernero, J.
    Vieira, M. C.
    Kponee-Shovein, K.
    Li, B.
    Cheng, M.
    Liu, J.
    Kang, H.
    Zhang, X.
    ANNALS OF ONCOLOGY, 2024, 35 : S44 - S45
  • [23] Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual patient (pt) data from the ARCAD database.
    Saad, Everardo D.
    Coart, Elisabeth
    Sommeijer, Dirkje Willemien
    Shi, Qian
    Zalcberg, John Raymond
    Burzykowski, Tomasz
    Meyers, Jeffrey P.
    Hoff, Paulo Marcelo
    Hecht, J. Randolph
    Hurwitz, Herbert
    Tol, Jolien
    Tebbutt, Niall C.
    Fuchs, Charles S.
    Diaz-Rubio, Eduardo
    Souglakos, John
    Falcone, Alfredo
    Kabbinavar, Fairooz F.
    Sargent, Daniel J.
    De Gramont, Aimery
    Buyse, Marc E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Capecitabine (X) plus weekly irinotecan (CAPIRI) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): findings from a phase II trial of the Brazilian Oncology Consordium
    Barrios, Carlos Henrique
    Viola, Fabiana
    Coura, Luciana
    Del Giglio, Auro
    Malhias, Clarissa
    ANNALS OF ONCOLOGY, 2004, 15 : 89 - 90
  • [25] Genetic variants of CBP and SOX9 to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI and bevacizumab (FOLFIRI/BEV)
    Ning, Yen
    Zhang, Wu
    Yang, Dongyun
    Stintzing, Sebastian
    Sunakawa, Yu
    Stremitzer, Stefan
    Sablo, Ana
    Yamauchi, Shinichi
    Matsusaka, Satoshi
    Zoratto, Federica
    Loupakis, Fotios
    El-Khoueiry, Rita Elie
    Barzi, Afsaneh
    El-Khoueiry, Anthony B.
    Kahn, Michael
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Treatment effects (TEs) of EGFR monoclonal antibodies (mAbs) in metastatic colorectal cancer (mCRC) patients (pts) with KRAS, NRAS, and BRAF mutation (MT) status: Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database.
    Karapetis, Christos Stelios
    Liu, Heshan
    Sorich, Michael
    Fiskum, Jack
    Grothey, Axel
    Van Cutsem, Eric
    Maughan, Tim
    Douillard, Jean-Yves
    Jonker, Derek J.
    Bokemeyer, Carsten
    Sobrero, Alberto F.
    Chibaudel, Benoist
    Zalcberg, John Raymond
    Adams, Richard
    Buyse, Marc E.
    De Gramont, Aimery
    Shi, Qian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): Preliminary results from a larger registry in the US
    Kozloff, M
    Cohn, A
    Christiansen, N
    Flynn, P
    Kabbinavar, F
    Robles, R
    Yood, MU
    Sarkar, S
    Hambleton, J
    Grothey, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 262S - 262S
  • [28] Impact of GABA pathway genes expression on first-line treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC): Data from CALGB/SWOG 80405 (Alliance).
    Battaglin, Francesca
    Yang, Yan
    Millstein, Joshua
    Soni, Shivani
    Algaze, Sandra
    Ashouri, Karam
    Mittal, Pooja
    Jayachandran, Priya
    Wong, Alexandra
    Lo, Jae Ho
    Torres-Gonzalez, Lesly
    Zhang, Wu
    Mulkerin, Daniel L.
    Ou, Fang-Shu
    Venook, Alan P.
    Innocenti, Federico
    Mumenthaler, Shannon M.
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Liver resection in patients (pts) treated with 1st line chemotherapy (CT) for metastatic colorectal cancer (mCRC) from Japanese cross-sectional cohort study (EMERaLD study)
    Iwamoto, S.
    Yoshioka, K.
    Tokuhara, K.
    Okazaki, S.
    Inoue, K.
    Michiura, T.
    Kwon, A.
    Amano, T.
    Ohashi, Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S548 - S548
  • [30] Prognostic factors for long-term overall survival (OS) for patients (pts) undergoing first-line treatment for metastatic colorectal cancer (mCRC) with chemotherapy (CT) plus bevacizumab (bev): Findings from a large observational study.
    Arnold, Dirk
    Grothe, Wilfried
    Tummes, Dirk
    Kindler, Manfred
    Petersen, Volker
    Boszeit-Luft, Stefanie
    Seraphin, Joerg
    Kutscheidt, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
12345